[go: up one dir, main page]

MX2021013111A - Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio. - Google Patents

Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio.

Info

Publication number
MX2021013111A
MX2021013111A MX2021013111A MX2021013111A MX2021013111A MX 2021013111 A MX2021013111 A MX 2021013111A MX 2021013111 A MX2021013111 A MX 2021013111A MX 2021013111 A MX2021013111 A MX 2021013111A MX 2021013111 A MX2021013111 A MX 2021013111A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
respiratory tract
tract infection
subunit vaccine
Prior art date
Application number
MX2021013111A
Other languages
English (en)
Inventor
Klaus Schwamborn
Andreas Meinke
Urban Lundberg
Fabien Perugi
Wolfgang Schüler
Original Assignee
Valneva Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Se filed Critical Valneva Se
Publication of MX2021013111A publication Critical patent/MX2021013111A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a proteínas F de hMPV modificadas estabilizadas en la conformación prefusión como candidatos a vacuna.
MX2021013111A 2019-05-20 2020-05-19 Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio. MX2021013111A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19175413 2019-05-20
PCT/EP2020/063973 WO2020234300A1 (en) 2019-05-20 2020-05-19 A subunit vaccine for treatment or prevention of a respiratory tract infection

Publications (1)

Publication Number Publication Date
MX2021013111A true MX2021013111A (es) 2021-11-17

Family

ID=66685352

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013111A MX2021013111A (es) 2019-05-20 2020-05-19 Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio.

Country Status (20)

Country Link
US (3) US12162907B2 (es)
EP (1) EP3972639A1 (es)
JP (1) JP2022533318A (es)
KR (1) KR20220010478A (es)
CN (1) CN114127101A (es)
AU (1) AU2020277661A1 (es)
BR (1) BR112021021637A2 (es)
CA (1) CA3138064A1 (es)
CL (1) CL2021002819A1 (es)
CO (1) CO2021014694A2 (es)
EC (1) ECSP21079178A (es)
GB (1) GB2598494B (es)
IL (1) IL287099A (es)
MX (1) MX2021013111A (es)
PE (1) PE20220400A1 (es)
PH (1) PH12021552736A1 (es)
SA (1) SA521430813B1 (es)
SG (1) SG11202110646PA (es)
WO (1) WO2020234300A1 (es)
ZA (1) ZA202106883B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
MX2021013111A (es) 2019-05-20 2021-11-17 Valneva Se Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio.
WO2021205017A1 (en) 2020-04-09 2021-10-14 Valneva Austria Gmbh Improvements in vaccine formulations for medical use
MX2023004078A (es) 2020-10-09 2023-05-24 Univ Texas Proteinas f de hmpv estabilizadas por prefusion.
CA3197971A1 (en) 2020-11-13 2022-05-19 Andrew Lawrence Feldhaus Protein-based nanoparticle vaccine for metapneumovirus
CA3210412A1 (en) 2021-04-09 2022-10-13 Urban Lundberg Human metapneumo virus vaccine
US20240335523A1 (en) * 2021-08-05 2024-10-10 The Regents Of The University Of California Glycoengineered Foldon Domains and Related Compositions and Methods
EP4448802A1 (en) * 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
WO2024167866A2 (en) * 2023-02-06 2024-08-15 Cyanvac Llc Modified piv5 vaccine vectors: methods of making and uses
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
CN119176858A (zh) * 2024-11-22 2024-12-24 北京华诺泰生物医药科技有限公司 一种重组人偏肺病毒融合前f蛋白纯化方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
US8568742B2 (en) 2000-06-08 2013-10-29 Valneva Austria Gmbh Methods and compositions involving immunostimulatory oligodeoxynucleotides
CA2418854A1 (en) 2000-08-17 2002-02-21 Jorg Fritz A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
WO2002094845A2 (en) 2001-05-21 2002-11-28 Intercell Ag Method for stabilising of nucleic acids
JP2005519035A (ja) 2001-12-07 2005-06-30 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシヌクレオチド
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
CA2523319A1 (en) * 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
EP2445527A2 (en) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
CN102145167A (zh) * 2010-02-05 2011-08-10 重庆医科大学附属儿童医院 重组人类偏肺病毒疫苗
PT2575876T (pt) 2010-05-26 2018-03-26 Selecta Biosciences Inc Vacinas de nanotransportadores sintéticos multivalentes
ES2930458T3 (es) 2011-12-06 2022-12-13 Valneva Austria Gmbh Compuestos de aluminio para su uso en agentes terapéuticos y vacunas
CL2013002829A1 (es) 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
EP3236998A1 (en) 2014-12-24 2017-11-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant metapneumovirus f proteins and their use
EP3718565B1 (en) 2015-10-22 2022-04-27 ModernaTX, Inc. Respiratory virus vaccines
US10961283B2 (en) 2016-06-27 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
WO2019092002A1 (en) * 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
MX2021013111A (es) 2019-05-20 2021-11-17 Valneva Se Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio.
CA3210412A1 (en) 2021-04-09 2022-10-13 Urban Lundberg Human metapneumo virus vaccine

Also Published As

Publication number Publication date
GB202114836D0 (en) 2021-12-01
AU2020277661A1 (en) 2021-10-21
US12162909B2 (en) 2024-12-10
CL2021002819A1 (es) 2022-07-08
US20250171501A1 (en) 2025-05-29
CO2021014694A2 (es) 2022-01-17
CN114127101A (zh) 2022-03-01
PH12021552736A1 (en) 2022-07-11
WO2020234300A1 (en) 2020-11-26
BR112021021637A2 (pt) 2021-12-21
SG11202110646PA (en) 2021-10-28
KR20220010478A (ko) 2022-01-25
CA3138064A1 (en) 2020-11-26
GB2598494A (en) 2022-03-02
GB2598494B (en) 2024-07-24
ECSP21079178A (es) 2021-11-30
IL287099A (en) 2021-12-01
US12162907B2 (en) 2024-12-10
US20220185847A1 (en) 2022-06-16
ZA202106883B (en) 2022-07-27
PE20220400A1 (es) 2022-03-22
JP2022533318A (ja) 2022-07-22
EP3972639A1 (en) 2022-03-30
SA521430813B1 (ar) 2024-04-27
US20240067681A1 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
CO2021014694A2 (es) Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio
AR118371A2 (es) Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-amina
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
MX375170B (es) Compuestos de amida para el tratamiento de vih.
BR112017005917A2 (pt) processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
MX2017010506A (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
CO6960552A2 (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
BR112016005270A2 (pt) compostos de aza-piridona, composições farmacêuticas e seus usos
MX2015012397A (es) Composiciones y metodos basados en anticuerpos neutralizados suministrados intranasalmente para eficacia terapeutica aumentada.
MX391440B (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
ES2510940R1 (es) Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
DOP2017000086A (es) Composiciones farmacéuticas de acción prolongada
MX378266B (es) Inhibidores de gingipaina de lisina.
MX2017002385A (es) Metodos y reactivos para la prevencion y/o el tratamiento de infecciones.
CO2020008887A2 (es) Inhibidores de pi4kiiiβ
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
MX377333B (es) Peptidos derivados de ezrina y composiciones farmaceuticas de los mismos.